Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova in severe hypertriglyceridemia
NL-OMON35729Phase 3Not yet recruiting
- Sponsor
- Omthera Pharmaceuticals
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia, sponsored by Omthera Pharmaceuticals. Primary endpoints: Change in fasting serum triglycerides and Safety and tolerability. Planned start Apr 2011; status: not yet recruiting.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON35729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35729.